Therapeutic vaccine design has shifted from shared self-antigens to tumour-specific mutations. Early-generation vaccines targeted self-derived antigens and, investigators reported, were constrained by immunological tolerance and suboptimal T cell priming. These older strategies produced measurable immune responses but rarely caused tumour regression. Personalized neoantigen vaccines, by contrast, target mutation-derived peptides that are not subject to central tolerance. The study team observed that neoantigen-directed vaccination now reliably induces CD4+ and CD8+ neoantigen-specific responses, moving immunogenicity away from being the main obstacle to clinical efficacy.
Vaccine platforms differ in how precisely they define epitopes and how strongly they activate antigen-presenting cells. The authors framed platforms as modulators of both antigen presentation and innate immune activation rather than as pure antigen-delivery systems. Peptide vaccines confer high control over defined epitopes but generally require exogenous adjuvants to activate dendritic cells. mRNA–LNP vaccines are multiplexable and possess self-adjuvanting properties, yet cellular translation and antigen-processing steps mean less predictable epitope presentation. Viral-vector vaccines can produce strong antigen expression and innate activation but face issues such as anti-vector immunity and safety constraints. Dendritic cell–based approaches allow ex vivo control of antigen loading and APC phenotype; the degree of epitope control depends on the chosen loading strategy. The authors emphasized that each approach trades epitope-level precision against intrinsic adjuvanticity and practical scalability.
Data indicated that vaccine immunogenicity is necessary but not sufficient for tumour control. The review enumerated a sequence of biological bottlenecks that limit translation of induced immunity into durable clinical benefit. First, antigen presentation can be limited by insufficient dendritic cell activation; delivering antigen with adjuvants that engage STING or toll-like receptors can enhance APC activation. Second, the quality and breadth of T cell priming matter—narrow or low-quality CD8+ responses may fail to generate robust antitumour activity. Including clonal neoantigens that present on both MHC class I and II can broaden engagement of CD8+ and CD4+ T cells. Third, trafficking and tumour infiltration are frequent barriers; the tumour microenvironment often excludes T cells, and combination strategies that remodel the microenvironment (for example, anti-angiogenic agents or chemokine modulators) were discussed as ways to improve infiltration. Fourth, chronic antigen exposure drives T cell exhaustion, which the authors linked to PD-1 expression and functional decline; combining vaccines with immune checkpoint blockade, co-stimulatory agonists or cytokine therapies may restore function. Fifth, tumour immune evasion—through antigen loss or downregulation of MHC class I—can blunt durable control; broadening antigen coverage and promoting epitope spreading were cited as potential counters.
Clinical benefit from vaccination depends strongly on timing and disease burden. The authors reported the clearest evidence for benefit in minimal residual disease and adjuvant settings after complete tumour resection. They cited phase III randomized-trial evidence in resected melanoma as an example where vaccination produced meaningful clinical outcomes. Trial-level signals in resected disease included a report that autogene cevumeran combined with atezolizumab and mFOLFIRINOX in resected pancreatic ductal adenocarcinoma was associated with prolonged recurrence-free survival and emerging overall survival signals. Similarly, intismeran autogene plus pembrolizumab produced randomized-trial evidence of benefit in resected stage IIIB–IV melanoma. In contrast, studies in advanced-stage and metastatic disease—such as trials of autogene cevumeran in advanced solid tumours and personalized neoantigen vaccination in advanced melanoma—have not consistently demonstrated clinical benefit despite persistent immunogenicity.
The authors described the neoadjuvant and perioperative window as a strategic opportunity to prime antitumour immunity while the intact tumour and its antigens are present. They outlined approaches where vaccination is given before surgery with concurrent checkpoint blockade or chemotherapy, followed by continued systemic therapy and optional post-operative vaccine boosting. This sequence provides a translational window: resected specimens can be analyzed for immune infiltration, antigen presentation and T cell function, which links mechanism to outcome. Trial examples include neoadjuvant vaccination schedules and combinations such as NECVAX-NEO1 or NeoVax sequences paired with anti-PD-1 therapy, although specific dosing and regimen details were not provided in the source.
The review set out priorities that remain to be addressed in the clinic. Authors noted the need for validated immune correlates of clinical benefit and for rational combination and sequencing strategies with immune checkpoint inhibitors. Confirmatory randomized trials in disease settings with promising signals—particularly adjuvant and minimal-residual-disease contexts—were highlighted. The team also recommended exploiting the neoadjuvant and perioperative window and exploring vaccination for cancer interception in high-risk individuals. Limitations in the field include the persistence of sequential biological barriers and the current lack of universally accepted biomarkers that predict which vaccinated patients will derive durable clinical benefit.